Aphrodisiac effect of VAJI-12 drug on Erectile dysfunction with or without premature ejaculation

Pharmaceutico - Therapeutic Study of VAJI-12 As Vajikaran

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/04/018642

Enrollment

100

Registered

2019-04-18

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- 100 Male patients with erectile dysfunction and premature ejaculation, which fulfilling the diagnostic criteria of Erectile Dysfunction and Premature ejaculation will be selected for the study Health Condition 2: N529- Male erectile dysfunction, unspecified Health Condition 3: N529- Male erectile dysfunction, unspecified

Interventions

Intervention1: VAJI-12: VAJI-12, in the dose of 3.137 gm twice/day with milk after meal for a period of 3 months with 3 follow ups of 30 days interval. Intervention2: VAJI-12: clinical trial under the

Eligibility

Inclusion criteria

Inclusion criteria: Male married patients suffering from Klaibya (ED) and Premature ejaculation

Exclusion criteria

Exclusion criteria: Age below 21 and above 50 years, Unmarried patients, Patients suffering from STD, Carcinoma, AIDS, congenital abnormalities of genital organs, other disease like Phimosis, Ulceration, Hydrocele, Spinal cord lesions, etc.

Design outcomes

Primary

Measure	Time frame
Effect of Research Drug will be assessed after 90 days duration with 3 followupsTimepoint: 90 days	—

Secondary

Measure	Time frame
NATimepoint: NA	—

Countries

India

Contacts

Public ContactAshutosh Pandey

Banaras Hindu University

anandayubhu@gmail.com9452074480

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026